Condition: Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD) · Sponsor: Novartis Pharmaceuticals
A study to assess safety, cellular kinetics and exploratory efficacy of rapcabtagene autoleucel in rheumatoid arthritis and Sjogren's disease
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · +41613241111 · novartis.email@novartis.com
Novartis Pharmaceuticals
Always discuss trial participation with your own doctor first.
| Novartis Investigative Site | Bordeaux, France | Recruiting |
| Novartis Investigative Site | Brest, France | Recruiting |
| Novartis Investigative Site | Le Kremlin-Bicêtre, France | Recruiting |
| Novartis Investigative Site | Lille, France | Recruiting |
| Novartis Investigative Site | Freiburg im Breisgau, Baden-Wurttemberg, Germany | Recruiting |
| Novartis Investigative Site | Göttingen, Lower Saxony, Germany | Recruiting |
| Novartis Investigative Site | Cologne, North Rhine-Westphalia, Germany | Recruiting |
| Novartis Investigative Site | Berlin, Germany | Recruiting |
| Novartis Investigative Site | Ulm, Germany | Recruiting |
| Novartis Investigative Site | Singapore, Singapore | Recruiting |
| Novartis Investigative Site | Barcelona, Spain | Recruiting |
| Novartis Investigative Site | Madrid, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07048197